Sjogrens Syndrome Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, Japan, UK - Size and Forecast 2024-2028

Sjogrens Syndrome Therapeutics Market Size 2024-2028

The sjogrens syndrome therapeutics market size is estimated to grow by USD 761.5 million at a CAGR of 6.78% between 2023 and 2028. The Sjogren's syndrome therapeutics market is experiencing significant growth, driven by a strong drug pipeline for launching innovative medicines. This pipeline includes biologics, which are gaining popularity due to their ability to target specific immune responses and reduce unwanted immunogenicity to therapeutic antigens. The market is further propelled by the increasing prevalence of Sjogren's syndrome, a chronic autoimmune disorder, and the rising awareness and diagnosis rates. However, challenges such as the complex nature of the disease and the lack of a definitive diagnostic test pose significant hurdles. Additionally, the high cost of biologic therapies and potential side effects may limit their widespread adoption. Despite these challenges, the market is expected to grow at a robust pace, fueled by ongoing research and development efforts.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

By Application 

The market share growth by the clinical segment will be significant during the forecast period. Market segmentation, also known as application segmentation, is a method of identifying different customer segments with unique needs and preferences in the context of a larger market. In the context of the global market for sjogrens syndrome therapeutics, this segmentation allows for product and service adjustments based on the specific clinical application needs of pharmaceutical companies and healthcare providers.

Get a glance at the market contribution of various segments View a PDF Sample

The clinical segment was valued at USD 882.60 million in 2018. Clinical therapeutics are also available to address the muscular-skeletal manifestations of sjogrens syndrome. This autoimmune condition can have a wide range of effects on tissues and structures, such as joints, muscles, and connective tissue, resulting in symptoms such as joint pain, muscle stiffness, and arthritis. Therefore, it is essential to provide tailored treatments for the improvement of mobility, comfort, and optimal functioning in response to these symptoms. These mentioned clinical uses will expand the growth of the global Sjorgens syndrome therapeutics market during the forecast period.

Type 

The primary sjogrens syndrome segment is a major segment of the global Sjogrens therapeutics market. Primary sjogrens syndrome is a systematic autoimmune disorder of the exocrine glands. The common symptoms include dryness in the mouth and eyes. Primary sjogrens syndrome is more prevalent among women than men. Women also experience dryness in the vagina. The symptoms are known as sicca symptoms, including xerophthalmia (dry eyes) and xerostomia (dry mouth). Although there are treatments available in the market for sicca symptoms, there is currently no cure for the condition. All these symptoms lead to a higher demand for Sjorgens syndrome therapeutics and thereby increase the growth of the market in focus.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. The growing incidence of autoimmune disorders drives the sjogrens syndrome therapeutics market in North America due to changing lifestyles such as taking a low-fat diet. According to the Centers for Disease Control and Prevention (CDC), autoimmune diseases are the third most common category in the US. It is also known that the majority of trials in developing treatment for Sjogren's Syndrome are carried out in Northern America. This will drive the growth of the sjogrens syndrome therapeutics market in North America. During the forecast period, upcoming approvals of therapeutic candidates by the US FDA (Food and Drug Administration)will drive market growth in the region.

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

ADVANZ PHARMA Corp. - The company offers sjogrens syndrome therapeutics such as a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, and endocrinology.

• AbbVie Inc.
• Biogen Inc.
• Bristol Myers Squibb Co.
• Daiichi Sankyo Co. Ltd.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Horizon Therapeutics Plc
• Johnson and Johnson
• MorphoSys AG
• Nicox S.A.
• Novartis AG
• Otsuka Holdings Co. Ltd.
• RemeGen Ltd.
• Resolve Therapeutics LLC
• Santen Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• TearSolutions Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

Sjogren's Syndrome is a chronic autoimmune disease that primarily affects the lacrimal and salivary glands, leading to weariness, joint discomfort, dry eyes, and dry mouth. The Sjogren's Syndrome Therapeutics Market caters to the development of treatments for this condition. The market comprises both over-the-counter (OTC) drugs and prescription medications. OTC drugs include counter eye drops for dry eyes and saliva substitutes for dry mouth. Prescription drugs include nonsteroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen for inflammation, and disease-modifying therapies for managing the disease's progression. Sjogren's Syndrome can also affect other organs such as the kidneys, lungs, intestines, and brain. Treatment options for these complications may involve surgical procedures. The Biotechnology industry is investing significantly in researching new therapeutics to address the symptoms and underlying causes of Sjogren's Syndrome. There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The high prevalence and incidence of Sjogren's syndrome is driving growth in the market.  Sjogren's Syndrome is a condition that can be associated with other immune disorders, for example, rheumatoid arthritis and lupus. The condition is more common in women than men. The incidence of sjogrens syndrome is rising globally. sjogrens syndrome is not fatal.

However, if it is left untreated, people can develop lymphoma, which can result in dental cavities, yeast infections, and vision problems. Due to changes in lifestyle and dietary habits, the prevalence of this disease is increasing. The prevalence of sjogrens syndrome depends on SLE. The high prevalence of sjogrens syndrome is expected to boost the market growth during the forecast period.

Significant Market Trends

The rising number of awareness programs is a key trend in the market. The Sjogren's Syndrome is currently the most common disease in the world. Dry mouth is not a trivial symptom for sjogrens syndrome patients as it has a considerable impact on their daily lives. Dry eye is one of the most common early symptoms of the disease.

There is an increase in efforts to educate eye care providers to identify and be aware of disease symptoms. When patients talk to their doctors about potential medical diagnostics and treatments, they also need to be informed and ready for action. Many organizations are focusing on increasing the awareness of sjogrens syndrome. Awareness programs will drive the global sjogrens syndrome therapeutics market during the forecast period.

Major Market Challenges

The unwanted immunogenicity of therapeutic antigens is a major challenge in the market. Undesirable immunogenicity occurs when the body's immune system responds to a therapeutic antigen. This reaction leads to the production of anti-drug antibodies (ADAs) that inactivate the therapeutic effects of the treatment. In rare cases, they can induce adverse effects. Immunogenicity is a major factor that can limit the use of therapeutics, which may hinder market growth. Immunosuppression, which may lead to opportunistic infections, is caused by the use of biologics.

Moreover, in order to treat rheumatoid arthritis, there is an increase in the introduction and use of biotherapeutics. The formation of immune complexes between ADAs and biologics may result in clearance, reduce serum biologic levels, and may have a more direct neutralizing effect on product-target binding. Such adverse effects can result in low patient compliance. This is eventually expected to hinder the growth of the global sjogrens syndrome therapeutics market during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Sjogrens Syndrome Therapeutics Market Customer Landscape

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Application Outlook 
  • Clinical
  • Hospital

• Type Outlook 
  • Primary
  • Secondary

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • South America
    • Chile 
    • Brazil 
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

You may also interested in the below market reports

• Dry Eye Syndrome Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Japan, Germany, China - Size and Forecast

• Autoimmune Hemolytic Anemia Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, Canada, UK, China - Size and Forecast

• Atopic Dermatitis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 

Market Analyst Overview

Sjogren's Syndrome is a chronic autoimmune disease affecting the lacrimal and salivary glands, leading to weariness, joint discomfort, dry eyes, and dry mouth. The disease's systemic consequences can also impact various organs like the kidneys, lungs, intestines, and brain. The biotechnology industry is focusing on developing novel therapeutics to address the unmet medical needs of Sjogren's Syndrome patients. Immunosuppressive medications, corticosteroids, biologic treatments, and immunomodulatory drugs are the primary treatment modalities for Sjogren's Syndrome. Inflammatory cytokines play a significant role in the disease's progression, making biomarker research and precision medicine techniques essential. Patient subgroups and holistic treatment modalities are gaining importance in the Sjogren's Syndrome therapeutics market.

Furthermore, ocular formulations, sustained release mechanisms, and nanoparticle-based therapies are some innovative approaches to improve patient outcomes. Telemedicine, rheumatologists, patient-reported outcomes, online support groups, and smartphone apps are transforming the way patients receive care and manage their symptoms. OTC drugs like counter eye drops and prescription drugs are commonly used to alleviate dry eyes and dry mouth symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are often prescribed to manage joint discomfort and inflammation. New treatments, like Ianalumab and antimalarial Quinolines, are under investigation to provide more effective and targeted therapies for Sjogren's Syndrome patients. Middle-aged women often seek symptomatic treatments for dry eyes, which can be addressed with artificial tears, OTC drug, or counter eye drops, while more severe cases might require a prescription drug or a surgical procedure to improve lacrimal gland function and tear production.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch